Emergent BioSolutions (EBS) Prelim. FY15 adj.-EPS Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Emergent Biosolutions Announces Preliminary 2015 Financial Results, Provides 2016 Financial Outlook, and Outlines New Five-Year (2016-2020) Strategic Growth Plan
January 11, 2016 7:01 AM EST2015 Preliminary Estimates:Total revenues of $520 to $525 million, a 16% increase over 2014 (at midpoint)GAAP net income of $60 to $64 million, a 69% increase over 2014 (at midpoint)Adjusted net income of $73 to $77 million, a 38% increase over 2014 (at midpoint)EBITDA of $130 to $134 million, a 43% increase over 2014 (at midpoint)Year-end cash of approximately $310 million2016 Forecast:Total revenues of $600 to $630 millionGAAP net income of $75 to $85 millionAdjusted net income of $90 to $100 millionEBITDA of $150 to $160 million  2020 Key Financial and... More
